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Original StudieS
Background: Parainfluenza viruses (PIV) have been shown to contribute 
substantially to pediatric hospitalizations in the United States. However, 
to date, there has been no systematic surveillance to estimate the burden 
among pediatric outpatients.
Methods: From August 2010 through July 2014, outpatient health care provid-
ers with enumerated patient populations in 13 states and jurisdictions partici-
pating in the Influenza Incidence Surveillance Project conducted surveillance 
of patients with influenza-like illness (ILI). Respiratory specimens were col-
lected from the first 10 ILI patients each week with demographic and clinical 
data. Specimens were tested for multiple respiratory viruses, including PIV1–4, 
using reverse transcriptase–polymerase chain reaction assays. Cumulative inci-
dence was calculated using provider patient population size as the denominator.
Results: PIVs 1–3 were detected in 8.0% of 7716 ILI-related outpatient 
specimens: 30% were PIV1, 26% PIV2 and 44% PIV3. PIV circulation 
varied noticeably by year and type, with PIV3 predominating in 2010–2011 
(incidence 110 per 100,000 children), PIV1 in 2011–2012 (89 per 100,000), 
dual predominance of PIV2 and PIV3 (88 and 131 per 100,000) in 2012–
2013 and PIV3 (100 per 100,000) in 2013–2014. The highest incidence of 
PIV detections was among patients aged <5 years (259–1307 per 100,000). 
The median age at detection for PIV3 (3.4 years) was significantly lower 
than the median ages for PIV1 (4.5 years) and PIV2 (7.0 years; P < 0.05).
Conclusions: PIVs 1–3 comprise a substantial amount of medically attended 
pediatric ILI, particularly among children aged <5 years. Distinct seasonal 
circulation patterns as well as significant differences in rates by age were 
observed between PIV types.
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ology, children
(Pediatr Infect Dis J 2016;35:717–722)
Parainfluenza viruses (PIVs) are a known cause of respiratory illness in children and contribute substantially to ambulatory 
care visits and hospitalizations in the United States, with rates of 
hospitalization estimated at 1.02 per 1000 among children aged <5 
years.1 The 4 distinct types of PIV are associated with specific clini-
cal presentations, causing a spectrum of respiratory illness. PIVs 1 
and 2 are the leading cause of croup in young children, and PIV1 
is isolated in most cases of croup. Infection with PIV3, often con-
sidered the most clinically severe of the PIVs, can lead to lower 
respiratory tract disease, bronchiolitis and pneumonia.2–5 Together, 
PIVs are second only to respiratory syncytial virus as a cause of 
hospitalization for respiratory tract illness (RTI) in young children.6
Outpatient and community studies have demonstrated the 
considerable impact of PIVs on pediatric respiratory disease outside 
the hospital setting; however, little has been published since the wide-
spread use of more sensitive molecular laboratory methods. Studies 
published in the 1990s demonstrated that PIVs were responsible for 
64%–65% of croup, 18%–45% of viral upper RTI and 22%–38% 
of viral lower RTI in children,2,7 and most children will experience 
infection with each PIV type by the time they reach 5 years of age.8 
Despite the substantial contribution of PIVs to respiratory illness, to 
date, there has been no systematic domestic surveillance to ascertain 
the population-based burden among pediatric outpatients.
The Influenza Incidence Surveillance Project (IISP) provides 
a unique opportunity to assess the age-specific burden of PIVs in 
outpatient practice across multiple years and a broad geographic 
range in the United States. Since 2010, the IISP has monitored the 
year-round incidence of influenza-like illness (ILI) and associated 
incidence of respiratory viruses, including PIVs 1–4, in a network 
of outpatient clinics across 13 US states and jurisdictions. Using 
IISP data from 2010 to 2014, we describe the seasonality and age-
specific burden of PIVs in the IISP, which will help to improve 
understanding of these viruses in the outpatient setting and support 
efforts for the prevention and treatment of PIV-associated illness.
MATERIALS AND METHODS
Influenza Incidence Surveillance Project and 
Parainfluenza Virus Surveillance
Detailed methodology for the IISP has been published previ-
ously.9,10 Briefly, surveillance was conducted year-round, with sur-
veillance years defined from August to July. We included data from 
12 state and local health departments (sites) from August 2010 to 
July 2013 and from 5 sites from August 2013 to July 2014 as fol-
lows: Florida, Los Angeles County, Minnesota (MN) and Wiscon-
sin (WI) from 2010 to 2014; Iowa, New Jersey, New York City, 
North Dakota, Oregon, Philadelphia and Virginia from 2010 to 
2013; Utah (UT) from 2010 to 2011; and Texas from 2011 to 2014. 
The IISP conducted nonresearch, public health surveillance.
Participating public health departments, or sites, recruited 
≈5 small to moderate sized outpatient healthcare providers (HCPs) 
with enumerated patient populations to report weekly age-specific 
counts of ILI and all-cause patient visits. Among patients aged 
≥2 years, ILI was defined as fever with cough or sore throat; among 
patients aged <2 years, fever with ≥1 of the following respiratory 
symptoms: cough, sore throat, nasal congestion or rhinorrhea. 
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Respiratory specimens (nasal, nasopharyngeal or oropharyngeal) 
were collected from the first 10 ILI patients each week along with 
demographic and clinical data; the sampling of up to 10 ILI patients 
each week ensured that a large proportion of all ILI patients would 
be sampled, given the small clinic size of HCPs.
Specimens were tested using molecular-based respiratory 
virus panels chosen by the participating laboratories: Los Angeles 
County, New Jersey, New York City, North Dakota, Texas and Vir-
ginia used Luminex xTAG respiratory virus panel (Luminex Diag-
nostics, Toronto, Canada); Florida, Iowa, MN, Oregon and Phila-
delphia used the virus-specific reverse transcriptase–polymerase 
chain reaction assay developed by Centers for Disease Control and 
Prevention11; UT and WI used ResPlex II v2.0 (Qiagen, Venlo, The 
Netherlands). PIVs 1–3 were included in the respiratory virus pan-
els at all health departments; PIV4 was included in the testing panel 
in MN, UT and WI. Information regarding proficiency testing was 
published previously.10
Data Analysis
Analysis was limited to children aged <18 years who met 
the ILI case definition, presented for care within 7 days of illness 
onset and were tested for PIV. Parainfluenza virus 4 detections were 
insufficient for analyses beyond overall proportions.
To identify PIV seasons, we calculated the weekly percent 
contribution or the percent of the entire surveillance year’s PIV 
positives that were detected each week. Onset of a season was 
defined as the first of 3 consecutive weeks with ≥2% of the speci-
mens contributing to the total yearly detections; the conclusion of 
a season was defined as the last of 3 consecutive weeks with ≥2% 
contribution. At least 4 consecutive weeks of ≥2% contribution 
were required to be determined as a season.
The proportion of ILI patients who tested positive for each 
PIV type each week, or the weekly percent positive, was multiplied 
by the weekly count of ILI patients to extrapolate the number of 
PIV-associated ILI visits. Incidence estimates were then calculated 
per 100,000 children, using the weekly patient population size as 
the denominator. Incidence estimates for individual weeks were 
summed by surveillance year to generate the cumulative incidence 
for each year and age group. Bootstrapping methods were used to 
calculate 95% confidence intervals of PIV rates.9,10.
Differences in seasonality between PIV types were demon-
strated by plotting the 3-week moving average of the extrapolated 
detection totals for each week for the 4 surveillance years; the 
3-week moving average was centered on the week reported and was 
used to better visualize the seasonal trends of each PIV.
To evaluate the frequency of symptoms included in the ILI 
case definition (fever, cough and sore throat) across the parainflu-
enza virus types, we used a subset of IISP data collected among 
sites that systematically conducted surveillance for more broadly 
defined acute respiratory illness (ARI). Patients with ARI were 
defined as having at least 2 respiratory symptoms, including fever, 
cough, sore throat, nasal congestion and rhinorrhea. These patients 
were inclusive of ILI, and sites followed the same methodology as 
previously described for ILI surveillance. Data from the following 
sites participating in ARI surveillance was included: MN and WI 
from 2010 to 2014; Iowa from 2010 to 2013; New Jersey and New 
York City from 2010 to 2012; and Florida, Los Angeles County, 
North Dakota, UT and Virginia from 2010 to 2011. All other symp-
toms were evaluated using data from ILI surveillance conducted by 
all sites in all years.
Demographic characteristics and symptoms were compared 
between PIV-positive and PIV-negative cases and across PIV types 
using the χ2 test for association. A P value of <0.05 was consid-
ered statistically significant. Relative risk and 95% CIs for PIV 
detections by age group were calculated using the 5–17-year age 
group as the reference. Analyses were conducted using SAS Ver-
sion 9.3 (SAS Institute Inc., Cary, NC).
RESULTS
From August 2010 to July 2014, a total of 114 HCPs par-
ticipated in IISP, ranging from 30–74 per year. Participating HCPs 
were primary care clinics (90%), urgent care (9%) and student 
health (1%) facilities. The clinics were split between rural (27%), 
suburban (32%) and urban (41%) locations, and 57% of the HCPs 
were identified as private organizations. The distribution of ages in 
the surveillance population was similar to the US population; 25% 
of the population was pediatric compared with 24% in the United 
States, with the following age distribution: 2% <12 months (US 
1%), 2% 12–24 months (US 1%), 4% 2–4 years (US 4%) and 16% 
5–17 years (US 17%).
PIVs Within the IISP Population
Among 560,941 pediatric outpatient visits, 19,277 (3.4%) 
were reported as ILI. Specimens were collected from 7716 (40%) 
children and tested for PIV 1–3; the distribution of PIV 1–3 detec-
tions by type are shown in Table 1. Among 2552 (33%) children 
tested for all 4 PIV types, 229 (9.0%) tested positive for at least 
one PIV, including 62 (2.4%) PIV1, 57 (2.2%) PIV2, 98 (3.8%) 
PIV3 and 12 (0.5%) PIV4. The distribution of virus types among 
all detections was 27% PIV1, 25% PIV2, 43% PIV3 and 5% PIV4. 
At least one additional respiratory virus was detected in 19% of 619 
children positive for PIV 1–3: most commonly, rhinovirus/entero-
virus (49%), adenovirus (23%), coronavirus (18%) and influenza 
(11%). Parainfluenza virus co-detections were identified in 5 chil-
dren (0.8%), including 1 PIV1/PIV2, 1 PIV3/PIV4, 1 PIV2/PIV3 
and 2 PIV1/PIV3. Across all years, 63% of ILI patients negative 
for PIV 1–3 tested positive for at least one respiratory virus (data 
not shown).
Parainfluenza Virus Seasonality
During the 4 surveillance years, PIV1 and PIV2 were most 
frequently detected in the fall and winter (Fig. 1). The PIV1 sea-
son generally lasted from October to January, with onset occurring 
between August 28 and October 29 and offset between January 1 
and March 17; the PIV2 season began between 16 September and 
23 October, but demonstrated a wide offset range between Novem-
ber 27 and March 13 (Fig. 2). Detection of PIV1 was significantly 
increased in odd-numbered years compared with even-numbered 
years (relative risk 6.1, 95% CI: 4.4–8.6), with a peak percent posi-
tive of 29% in elevated seasons. Conversely, PIV2 detections were 
significantly higher in even-numbered years as compared with odd 
years (odds ratio 2.4, 95% CI: 1.6–3.6) with a peak between 14% 
and 22% positive. PIV3 demonstrated an annual spring with an 
onset between February 3 and April 13 and offset between April 21 
and July 22 (Fig. 1), and peak percent positive between 17% and 
33%. The percent of ILI patients with PIV3 detected was signifi-
cantly lower in odd-numbered years compared with even-numbered 
years, when circulation of PIV1 was elevated (P < 0.05). During the 
2012–2013 surveillance year, 2 time periods met PIV3 season cri-
teria, including 14 weeks from September to December 2012 and 
12 weeks from February to April 2013; detections occurring during 
January and February did not meet season criteria (Fig. 2). Circula-
tion patterns of PIV1, 2 and 3 were evaluated by geographic region 
and found to be consistent across the United States.
Burden of PIVs by Surveillance Year
The incidence of parainfluenza virus-associated ILI visits 
varied significantly by surveillance year and virus type (see Table, 
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Supplemental Digital Content 1, http://links.lww.com/INF/C419, 
which provides incidence of parainfluenza virus-associated ILI 
by surveillance year and age group). In 2010–2011, PIV3 pre-
dominated (110 per 100,000 children), while PIV1 predominated 
in 2011–2012 (89 per 100,000 children). The 2012–2013 sur-
veillance year was characterized by dual-predominance of PIV2 
and PIV3 (88 and 131 per 100,000 children, respectively), and 
in 2013–2014, PIV3 predominated (100 per 100,000 children). 
A particularly high burden of PIV was observed in 2012–2013, 
indicated by an incidence of PIV-associated visits of 251 per 
100,000 children and age-specific incidence ranging from 367 to 
1307 per 100,000 children.
Burden of PIVs by Age
Children with any PIV detection were significantly younger 
than PIV-negative children (median age 4.7 vs. 6.3 years, respec-
tively; P < 0.05). Sixty-three percent of PIV 1–3 detections were 
in children aged <5 years, and age varied significantly between 
each of the PIV types. Parainfluenza virus 3 affected significantly 
younger children than PIV1 or PIV2 (median age = 3.3 years; 
P < 0.05), while PIV2 affected older children than the other PIV 
types (median age = 7.1 years; P < 0.05; Table 1).
Figure 3 demonstrates the variation in cumulative incidence 
of PIV types by age group and surveillance year. The burden of 
PIV3 tended to be highest among children aged 1 to <2 years in 
TABLE 1. Distribution by Age Group and Surveillance Year of Pediatric Outpatients With ILI Tested for PIV 1–3, 
August 2010 to July 2014
Patients Tested 
for PIV
PIV Positive 
(1–3) PIV Negative P Value
Parainfluenza Detections
P ValuePIV-1 PIV-2 PIV-3
7716 (100.0) 619 (8.0) 7097 (92.0) <0.0001 185 (29.7) 162 (26.0) 276 (44.3) <0.0001
Age group
  <1 year 734 (9.5) 64 (10.3) 670 (9.4) <0.0001 17 (9.2) 7 (4.3) 40 (14.5) <0.0001
  1-<2 years 980 (12.7) 105 (17.0) 875 (12.3) 24 (13.0) 6 (3.7) 76 (27.5)
  2–4 years 1932 (25.1) 221 (35.7) 1711 (24.1) 75 (40.5) 43 (26.5) 105 (38.0)
  5–17 years 4067 (52.7) 229 (37.0) 3838 (54.1) 69 (37.3) 106 (65.4) 55 (19.9)
Median age (years) 6.2 4.7 6.3 <0.0001 4.5 7.0 3.4 <0.0001
Season
  2010–11 2658 (34.5) 187 (7.0) 2471 (93.0) 0.078 20 (10.7) 54 (28.9) 116 (62.0) <0.0001
  2011–12 1950 (25.3) 169 (8.7) 1781 (91.3) 114 (67.5) 22 (13.0) 33 (19.5)
  2012–13 2405 (31.2) 211 (8.8) 2194 (91.2) 24 (11.4) 79 (37.4) 109 (51.7)
  2013–14 703 (9.1) 52 (7.4) 649 (92.6) 27 (51.9) 7 (13.5) 18 (34.6)
Comparison of age distribution across 
PIV-positive, PIV types and  
PIV-negative patients
Odds ratio (95% CI) for a pediatric ILI patient in the <1, 1–2 or 2–4 age group to have a positive PIV 
test, compared with the 5–17 year age group
  <1 year 1.6 (1.2–2.0) 1.4 (0.8–2.3) 0.4 (0.2–0.8) 4 (2.7–6.0)
  1-<2 years 1.9 (1.6–2.4) 1.4 (0.9–2.3) 0.2 (0.1–0.5) 5.7 (4.1–8.1)
  2–4 years 2 (1.7–2.4) 2.3 (1.7–3.2) 0.9 (0.6–1.2) 4 (2.9–5.5)
  5–17 years REF REF REF REF
REF indicates referent category.
FIGURE 1. The extrapolated* weekly number (3-week average) of PIV-associated ILI visits among pediatric outpatients, 
August 2010 through July 2014. *Extrapolated counts of PIV-associated ILI visits were calculated as the weekly proportion of 
PIV-positive ILI visits multiplied by the weekly count of ILI visits.
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all years (range by season 222–868 per 100,000 children). Dur-
ing biennial years of elevated circulation, the incidence of PIV1- 
associated and PIV2-associated visits was greatest in children 
aged 2 to 4 years (388 and 273 per 100,000 children for PIV1 in 
2011–2012 and 2013–2014; 193 and 412 per 100,000 children for 
PIV2 in 2010–2011 and 2012–2013). In general, PIV3 affected 
children aged <2 years more frequently than PIV1 or PIV2 
with the exception of 2011–2012 when PIV1 overwhelmingly 
predominated (Fig. 3 and Table, Supplemental Digital Content 1, 
http://links.lww.com/INF/C419).
Comparative Symptomatology of PIVs
Among children presenting with more broadly defined ARI, 
79% (282/355) of PIV-positive children met ILI case criteria, which 
did not vary significantly by PIV type or age group (see Table, 
Supplemental Digital Content 2, http://links.lww.com/INF/C420, 
which provides symptomatology of PIV-associated ILI and ARI). 
Children with ARI and any PIV detection were more likely to have 
cough (91%) and fever (80%) compared with PIV-negative ARI 
children (P < 0.05). PIV2 was detected more frequently among 
children with sore throat (71%) than were PIV1 (55%) or PIV3 
(35%; P < 0.05). Among children presenting with ILI, myalgia 
and chills were reported significantly more frequently among PIV-
negative ILI patients as compared with PIV-positive ILI patients 
(P < 0.05). Children with ILI and PIV3 were 1.7 times as likely to 
report rhinorrhea compared with those with PIV1 or PIV2 (95% 
CI: 1.4–2.0).
DISCUSSION
PIVs represented a substantial burden of respiratory ill-
nesses among children in IISP, accounting for 9% of all ILI-related 
pediatric outpatient visits overall and up to 33% of visits at season 
peak. Consistent annual spring PIV3 and biennial fall PIV1 and 
PIV2 epidemics were observed across 4 years, yielding an ILI visit 
incidence range by season of 130–251 visits per 100,000 children. 
The incidence of PIV-associated visits was highest among children 
aged <5 years, and we also observed substantial variation by age 
for PIV types.
Each PIV type demonstrated unique and distinct seasonal 
circulation patterns, consistent with previous studies.6,7,12 PIVs 1 
and 2 in the IISP circulated annually in the fall but caused alternat-
ing biennial epidemics, with substantial seasons of PIV1 in odd 
years and PIV2 in even years. Annual spring epidemics of PIV3 
were observed, but PIV3 circulation was significantly reduced 
during odd years of elevated PIV1 circulation. Prior studies have 
attributed this inverse pattern of activity to viral interference and 
cross-protection of PIV1 and PIV3 antibodies, producing consist-
ent PIV seasonality.3,5,7,12,13 Patterns of PIV2 circulation were varied, 
and we were unable to identify any season onset during 2013–2014. 
Seasonality findings for PIV2 have varied over the last half century 
and include reports of annual, biannual or biennial seasonality in 
either even or odd years, or irregular activity,1,3,6,14–17 and may be 
explained by evolving seasonality, regional variability, difficulties 
in virus isolation or sample size limitations.2,7,12,18,19 Consistent with 
FIGURE 2. Seasonal circulation of PIV 1–3 detections across 12 months, by surveillance year, August 2010 through July 
2014. *A PIV2 season was not detected during the 2013–2014 surveillance year.
FIGURE 3. Comparison by surveillance year of age-specific 
cumulative incidence estimates of PIV 1–3-associated 
outpatient visits per 100,000 children, August 2010 
through July 2014.
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previous studies, PIV4 was too infrequently detected to identify 
any circulation patterns or associated epidemiologic trends, but 
comprised 5% of all PIV detections.12,14
PIVs contribute substantially to the burden of medically 
attended ILI in children, accounting for 9% of ILI-related pediatric 
outpatient visits and 12% among children aged <5 years. Compara-
ble estimates from 2 recent studies were found,20,21 though our esti-
mates were higher than many other estimates of non-hospitalized 
PIV which used more broadly defined case definitions, less sensi-
tive testing methods or included adults.2,8,13 Corresponding cumula-
tive incidence estimates from IISP suggest that PIVs are detected 
among pediatric outpatients aged <5 years at a rate of 259–1307 
visits per 100,000 children, compared with estimates of 180–2740 
per 100,000 children for influenza virus.9,10. Trends in the detection 
of PIV among pediatric outpatients are consistent with previous 
estimates among children with acute respiratory and/or febrile ill-
nesses7; however, population-based rates of PIV outpatient visits 
among children are unique to IISP.
PIVs were shown to have a substantial burden among chil-
dren aged <5 years, and variation in detection by age was observed 
between PIV types. In particular, PIV3 affected younger children 
than either PIV1 or PIV2 and was significantly more likely to be 
detected in children aged <2 years than those aged ≥2 years. These 
observed age patterns have been well-established.2,4,7,22 PIV3 has 
been shown to have the lowest median age among respiratory 
viruses14 and infects most children by age 2, with high rates of rein-
fection among the very young, while PIV1 and PIV2 each infect 
most children by age 5.2,4,6,8,13 Detections of PIV in very young 
children may be attributable to less mixing among preschool aged 
children, which may lead to a build-up of immunologically suscep-
tible children and seasonal epidemics among the very young.13 This 
analysis supports previous findings that viral co-detections are fre-
quent among young PIV-positive children, with estimates around 
20%.22,23 High rates of co-detection may be attributable to immature 
immune systems and prolonged viral shedding in the very young; 
however, whether co-detections lead to increased severity among 
outpatients is unclear.23
Analysis of symptom data demonstrated that fever and 
cough were associated with PIV positivity among patients pre-
senting with ARI. Although cough is reported consistently in PIV 
cases,24 the presence of fever among PIV-positive patients present-
ing with symptoms of RTI varies widely in the literature, with esti-
mates between 33% and 80%.2,5,22 The difference in fever presenta-
tion across PIV studies may be attributable to differences in study 
populations, but most analyses assess clinical diagnoses rather than 
symptomatology.
The IISP is a well-established respiratory virus surveil-
lance network; however, this analysis was nevertheless subject to 
limitations. The IISP reflects ILI in the outpatient setting; thus, our 
analysis does not capture PIV patients with non-ILI presentation. 
However, we found that among a limited number of sites conduct-
ing surveillance including all ARI patients, 79% of the PIV-posi-
tive patients reported ILI symptoms within the 7 days before the 
clinical visit. As a more sensitive case definition, we expect that 
surveillance of ARI patients would have produced greater numbers 
of PIV cases than ILI surveillance; however because of decreased 
specificity, the percent positivity of PIV among ARI patients 
would be lower than among ILI patients. Surveillance for PIVs 
was reduced in the 2013–2014 surveillance year from 12 to 5 par-
ticipating health departments, leading to decreased PIV detections 
for that year; although PIV data from 2013 to 2014 was consist-
ent with previous surveillance years, the analysis may have been 
subject to bias related to decreased specimen collection and test-
ing. Finally, although all sites used sensitive and specific reverse 
transcriptase–polymerase chain reaction assays for PIV detection, 
small differences between the assays may have resulted in minor 
differences in PIV detection.
It is well-established that PIVs contribute substantially to 
ILI morbidity and hospitalization among children, being second 
only to respiratory syncytial virus in hospitalizations because of 
respiratory tract infections among children aged <5 years.2,3,6,16,25 
Here we use population-based surveillance data to calculate the 
incidence of ILI visits and demonstrate the appreciable contribu-
tion of PIVs to respiratory illness among children in the outpatient 
setting. Although PIVs are the leading cause of croup and con-
tribute substantially to rates of upper and lower respiratory tract 
disease among children, there are currently no available antivirals 
or vaccines to treat PIV infection. Because PIV infections may be 
clinically indistinguishable from other ILI etiologies, it is important 
that surveillance be conducted to provide a resource to inform clini-
cians of viral circulation. We demonstrated the consistent seasonal-
ity and high-risk age groups which may help outpatient providers 
to better identify the etiology of PIV-related illness. Furthermore, 
population-based estimates of the incidence of PIV-associated out-
patient ILI visits improve our understanding of the circulation and 
burden of PIV and support efforts for the prevention and treatment 
of infections, including the development of a PIV vaccine for very 
young children.
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